



CPE Monitor Activity Transcript

Participant Name: Maryam Mary Khazraee
NABP e-Profile ID: 936070
CPE Activity Date Range: 01/01/2025 to 12/31/2025
Total CPE Hours Earned: 30.75

Recorded CPE activity for the period of 01/01/2025 to 12/31/2025 . Please allow 35 days for the CPE Provider to process your CPE and submit it through the CPE Monitor System. If it has been more than 35 days since you submitted the necessary information for CPE credit, please contact the CPE Provider.

Activity Date	Activity #	Credit Type	Source	Title	Topic	Provider	Live Hours	Home Hours
6/25/2025	0669-0000-23-020-H03-P	ACPE	ACPE	Ethics in Pharmacy Practice	Law Related to Pharmacy Practice	RxCe.com LLC	0.00	1.00
6/25/2025	0669-0000-24-121-H05-P	ACPE	ACPE	Medication Errors and Florida Reporting Rules	Patient Safety	RxCe.com LLC	0.00	2.00
6/25/2025	0669-0000-24-127-H08-P	ACPE	ACPE	Validation and Counseling of Prescriptions for Controlled Substances and Opioids	Opioids/Pain Management/Substance Use Disorder	RxCe.com LLC	0.00	2.00
3/23/2025	0290-0000-25-013-L08-P	ACPE	ACPE	Advancing Acute Pain Care: Breakthrough Non-Opioid Therapies and the Pharmacist's Critical Role	Opioids/Pain Management/Substance Use Disorder	Pharmacy Times Office of Continuing Professional Education	1.50	0.00
3/22/2025	0290-0000-25-012-L02-P	ACPE	ACPE	Exploring HIV Long-Acting Injectable Uptake: How Pharmacists Can Encourage Long-Acting Injectables to Stem the Spread of HIV	HIV/AIDS	Pharmacy Times Office of Continuing Professional Education	1.50	0.00

3/15/2025	0290-0000-25-036-L99-P	ACPE	ACPE	Beyond the Prescription: Tackling Social Isolation for Better Health		Additional Topic Areas	Pharmacy Times Office of Continuing Professional Education	0.50	0.00
3/15/2025	0290-0000-25-037-L01-P	ACPE	ACPE	Evaluating the Role of Pharmacists in Utilizing Potassium-Competitive Acid Blockers for Acid Peptic Disorders	Disease State Management/Drug Therapy	Pharmacy Times Office of Continuing Professional Education	1.00	0.00	
3/15/2025	0290-0000-25-038-L03-P	ACPE	ACPE	Discipline Decoded: Navigating Pharmacy Law and Disciplinary Cases	Law Related to Pharmacy Practice	Pharmacy Times Office of Continuing Professional Education	1.00	0.00	
3/15/2025	0290-0000-25-040-L08-P	ACPE	ACPE	Balancing Pain Management and Opioid Use Disorder: Recognition, Treatment, and Compassionate Communication in Pharmacy Practice	Opioids/Pain Management/Substance Use Disorder	Pharmacy Times Office of Continuing Professional Education	1.00	0.00	
3/15/2025	0290-0000-25-041-L06-P	ACPE	ACPE	Empowering Pharmacists in Travel Medicine: Enhancing Patient Care Through Vaccination, Prevention, and Education	Immunizations	Pharmacy Times Office of Continuing Professional Education	2.00	0.00	
3/15/2025	0290-0000-25-042-L06-P	ACPE	ACPE	Respiratory Syncytial Virus Disease Prevention in Adults: The Pharmacists Role in Improving Vaccine Uptake	Immunizations	Pharmacy Times Office of Continuing Professional Education	1.00	0.00	
3/15/2025	0290-0000-25-043-L01-P	ACPE	ACPE	Understanding and Personalizing Chronic Obstructive Pulmonary Disease Diagnosis and Treatment	Disease State Management/Drug Therapy	Pharmacy Times Office of Continuing Professional Education	1.00	0.00	
2/17/2025	JA0002895-0000-22-056-H04-P	IPCE	ACPE	Reporting and Public Viewing of Individual Case Safety Reports (ICSRs)	Pharmacy Administration	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00	
2/17/2025	JA0002895-0000-23-015-H01-P	IPCE	ACPE	Understanding Generic Narrow Therapeutic Index Drugs	Disease State Management/Drug Therapy	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00	

2/17/2025	JA0002895-0000-23-025-H99-P	IPCE	ACPE	The Safety Evaluation and Surveillance of Generic Drugs	Additional Topic Areas	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.50
2/17/2025	JA0002895-0000-23-074-H01-P	IPCE	ACPE	Biosimilars: A Review of Scientific, Regulatory, and Clinical Considerations for Health Care Providers	Disease State Management/Drug Therapy	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00
2/17/2025	JA0002895-0000-23-092-H05-P	IPCE	ACPE	Naltrexone Injection for Opioid Use Disorder - FDAs Efforts to Reduce Medication Errors	Patient Safety	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00
2/17/2025	JA0002895-0000-24-034-H99-P	IPCE	ACPE	Advancing Transparency and Regulatory Science Activities on the Risk Evaluation and Mitigation Strategy (REMS)	Additional Topic Areas	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00
2/17/2025	JA0002895-0000-24-035-H99-P	IPCE	ACPE	An Overview of FDA's Project Facilitate Oncology Expanded Access Program	Additional Topic Areas	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00
2/17/2025	JA0002895-0000-24-062-H99-P	IPCE	ACPE	FDA Rare Disease Day 2024: Clinical Trial Foundations and Future Directions	Additional Topic Areas	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.75
2/17/2025	JA0002895-0000-24-064-H99-P	IPCE	ACPE	FDA Rare Disease Day 2024: Navigating Information. Empowering Patients and Providers	Additional Topic Areas	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	2.00

2/17/2025	JA0002895-0000-24-065-H99-P	IPCE	ACPE	FDA Rare Disease Day 2024: FDA Initiatives	Additional Topic Areas	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00
2/17/2025	JA0002895-0000-24-072-H01-P	IPCE	ACPE	Tips to Navigating Drug Interaction information in the US Prescribing Information	Disease State Management/Drug Therapy	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00
2/17/2025	JA0002895-0000-24-096-H99-P	IPCE	ACPE	Important Orange Book Facts	Additional Topic Areas	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00
2/17/2025	JA0002895-0000-24-102-H99-P	IPCE	ACPE	The Bad Ad Program	Additional Topic Areas	Food & Drug Administration - Center for Drug Evaluation & Research	0.00	1.00

Disclaimer: The National Association of Boards of Pharmacy® (NABP®) generated this Activity Transcript (Transcript) or Compliance Report (Report) from NABP's systems. The Transcript or Report contains information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) and, if applicable, information from you, the non-ACPE course participant (Participant). The Transcript or Report can be used as proof of CPE credit for ACPE-accredited CPE. The ACPE provider is responsible for the accuracy of the ACPE course data and Participant is responsible for the accuracy of the non-ACPE course data on this Transcript or Report. Requests for changes to ACPE activity data must be directed to the ACPE-accredited provider that offered the activity. You are responsible for verifying that this Transcript or Report accurately reflects all continuing pharmacy education you participated in, whether ACPE-accredited or not. CPE Monitor Plus is unable to track CPE hours or CPE completion for specialty licenses, including without limitation, pharmacist-in-charge and immunizer licenses; you are responsible for tracking CPE hours for specialty licenses. If there is a discrepancy between this Transcript or Report and the data contained in the NABP systems or your records, please contact the NABP CPE Monitor Team at cpemonitor@nabp.pharmacy. **Boards of pharmacy, not NABP, determine CPE compliance.** Participant attested that any non-ACPE course data submitted to NABP is true and correct, that Participant complied with the NABP Terms of Use, and accepts full responsibility for all information submitted to NABP and the accuracy of their Transcript or Report.